Amneal Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2026 was $0.41.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.29.
During the past 12 months, the average EBIT per Share Growth Rate of Amneal Pharmaceuticals was 18.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -0.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Amneal Pharmaceuticals's EBIT per Share or its related term are showing as below:
AMRX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -27.5 Med: -4.1 Max: 22
Current: -0.7
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Amneal Pharmaceuticals was 22.00% per year. The lowest was -27.50% per year. And the median was -4.10% per year.
AMRX's 3-Year EBIT Growth Rate is ranked worse than 63.21% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs AMRX: -0.70
Amneal Pharmaceuticals (NAS:AMRX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Amneal Pharmaceuticals EBIT per Share Related Terms
Amneal Pharmaceuticals EBIT per Share Historical Data
* Premium members only.
The historical data trend for Amneal Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.29
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (AMRX) has a EBIT per Share of $1.29 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Amneal Pharmaceuticals and its competitors. According to the industry distribution chart, Amneal Pharmaceuticals ranks #512 out of 810 companies in the Drug Manufacturers industry, placing it in the top 63.2%.
Is Amneal Pharmaceuticals' EBIT per Share too high?
Amneal Pharmaceuticals' current EBIT per Share is $1.29. The Drug Manufacturers industry median EBIT per Share is 7.65. Amneal Pharmaceuticals' value of $1.29 is 83.1% below this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #512 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' EBIT per Share compare to INDV and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #512 out of 810 companies for EBIT per Share. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median EBIT per Share is 7.65. Amneal Pharmaceuticals' value of $1.29 is 83.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current EBIT per Share of $1.29 is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Amneal Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current EBIT per Share is $1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.57, compared to a current price of $16.98 — trading 124.3% above its estimated fair value. The current EBIT per Share is $1.29 and 83.1% below the Drug Manufacturers industry median of 7.65. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current EBIT per Share is $1.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.98 is trading 124.3% above its estimated GF Value™ of $7.57.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
EBIT per Share: $1.29
GF Value™: $7.57 vs. price of $16.98 (124.3% above fair value)
Industry Position: 83.1% below the Drug Manufacturers median (#512 of 810)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
63GF Score
Get the complete analysis for AMRX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
